Jeune Inc. is a biotechnology company leveraging a clinically validated gene-delivery platform to fundamentally address – and reverse – the biology of aging or photo-damaged skin.

Jeune was formed in April 2019 by Krystal Biotech to advance a portfolio of innovative treatments that address aesthetic skin conditions. Our product candidates are based on Krystal’s Skin TARgeted Delivery platform, or STAR-D platform. This skin-optimized gene delivery technology enables us to specifically target key cells in the skin for delivery of a desired effector (gene). In doing so, we aim to stimulate a patient’s own cells to produce the important structural proteins that normally decline over time as we age (intrinsic aging) and with photo-damage (extrinsic aging).

Jeune’s pipeline of innovative treatments are designed to directly address the biology of aging skin by stimulating a patient’s own cells to produce the proteins that keep skin looking younger and healthier.